vs
CENTURY ALUMINUM CO（CENX）与HAEMONETICS CORP（HAE）财务数据对比。点击上方公司名可切换其他公司
CENTURY ALUMINUM CO的季度营收约是HAEMONETICS CORP的1.9倍（$633.7M vs $339.0M），HAEMONETICS CORP净利率更高（13.2% vs 0.3%，领先12.9%），CENTURY ALUMINUM CO同比增速更快（0.4% vs -2.7%），HAEMONETICS CORP自由现金流更多（$87.2M vs $67.7M），过去两年CENTURY ALUMINUM CO的营收复合增速更高（13.8% vs 0.4%）
世纪铝业是总部位于美国的原铝生产商，在美国肯塔基州、南卡罗来纳州及冰岛均设有铝生产工厂，是美国规模最大的原铝生产商，在纳斯达克上市，总部坐落于芝加哥南瓦克尔大道1号。
豪洛捷（Haemonetics）是全球血液与血浆供应及服务提供商，于20世纪70年代由艾伦·（杰克）·莱瑟姆博士在马萨诸塞州内蒂克创立，业务围绕血液相关产品及配套服务展开，为全球医疗领域提供血液管理相关的专业解决方案。
CENX vs HAE — 直观对比
营收规模更大
CENX
是对方的1.9倍
$339.0M
营收增速更快
CENX
高出3.2%
-2.7%
净利率更高
HAE
高出12.9%
0.3%
自由现金流更多
HAE
多$19.5M
$67.7M
两年增速更快
CENX
近两年复合增速
0.4%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $633.7M | $339.0M |
| 净利润 | $1.8M | $44.7M |
| 毛利率 | 13.0% | 59.7% |
| 营业利润率 | 5.2% | 19.9% |
| 净利率 | 0.3% | 13.2% |
| 营收同比 | 0.4% | -2.7% |
| 净利润同比 | -96.0% | 19.3% |
| 每股收益（稀释后） | $0.03 | $0.95 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CENXHAE
| Q4 25 | $633.7M | $339.0M | ||
| Q3 25 | $632.2M | $327.3M | ||
| Q2 25 | $628.1M | $321.4M | ||
| Q1 25 | $633.9M | $330.6M | ||
| Q4 24 | $630.9M | $348.5M | ||
| Q3 24 | $539.1M | $345.5M | ||
| Q2 24 | $560.8M | $336.2M | ||
| Q1 24 | $489.5M | — |
净利润CENXHAE
| Q4 25 | $1.8M | $44.7M | ||
| Q3 25 | $14.9M | $38.7M | ||
| Q2 25 | $-4.6M | $34.0M | ||
| Q1 25 | $29.7M | $58.0M | ||
| Q4 24 | $45.2M | $37.5M | ||
| Q3 24 | $47.3M | $33.8M | ||
| Q2 24 | $-2.5M | $38.4M | ||
| Q1 24 | $246.8M | — |
毛利率CENXHAE
| Q4 25 | 13.0% | 59.7% | ||
| Q3 25 | 12.2% | 59.5% | ||
| Q2 25 | 5.8% | 59.8% | ||
| Q1 25 | 9.6% | 58.4% | ||
| Q4 24 | 10.5% | 55.5% | ||
| Q3 24 | 15.2% | 54.2% | ||
| Q2 24 | 3.6% | 52.0% | ||
| Q1 24 | 3.4% | — |
营业利润率CENXHAE
| Q4 25 | 5.2% | 19.9% | ||
| Q3 25 | 9.2% | 17.9% | ||
| Q2 25 | 3.3% | 16.8% | ||
| Q1 25 | 7.3% | 21.6% | ||
| Q4 24 | 7.8% | 16.9% | ||
| Q3 24 | 11.8% | 15.0% | ||
| Q2 24 | 1.1% | 11.8% | ||
| Q1 24 | 0.4% | — |
净利率CENXHAE
| Q4 25 | 0.3% | 13.2% | ||
| Q3 25 | 2.4% | 11.8% | ||
| Q2 25 | -0.7% | 10.6% | ||
| Q1 25 | 4.7% | 17.5% | ||
| Q4 24 | 7.2% | 10.8% | ||
| Q3 24 | 8.8% | 9.8% | ||
| Q2 24 | -0.4% | 11.4% | ||
| Q1 24 | 50.4% | — |
每股收益（稀释后）CENXHAE
| Q4 25 | $0.03 | $0.95 | ||
| Q3 25 | $0.15 | $0.81 | ||
| Q2 25 | $-0.05 | $0.70 | ||
| Q1 25 | $0.29 | $1.17 | ||
| Q4 24 | $0.58 | $0.74 | ||
| Q3 24 | $0.46 | $0.66 | ||
| Q2 24 | $-0.03 | $0.74 | ||
| Q1 24 | $2.26 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $134.2M | $363.4M |
| 总债务越低越好 | — | $1.2B |
| 股东权益账面价值 | $805.6M | $911.5M |
| 总资产 | $2.3B | $2.5B |
| 负债/权益比越低杠杆越低 | — | 1.34× |
8季度趋势，按日历期对齐
现金及短期投资CENXHAE
| Q4 25 | $134.2M | $363.4M | ||
| Q3 25 | $151.4M | $296.4M | ||
| Q2 25 | $40.7M | $292.9M | ||
| Q1 25 | $44.9M | $306.8M | ||
| Q4 24 | $32.9M | $320.8M | ||
| Q3 24 | — | $299.3M | ||
| Q2 24 | $41.3M | $344.4M | ||
| Q1 24 | $93.5M | — |
总债务CENXHAE
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CENXHAE
| Q4 25 | $805.6M | $911.5M | ||
| Q3 25 | $741.8M | $849.2M | ||
| Q2 25 | $724.4M | $882.3M | ||
| Q1 25 | $726.3M | $820.8M | ||
| Q4 24 | $694.4M | $906.9M | ||
| Q3 24 | $628.5M | $878.9M | ||
| Q2 24 | $601.5M | $905.4M | ||
| Q1 24 | $601.5M | — |
总资产CENXHAE
| Q4 25 | $2.3B | $2.5B | ||
| Q3 25 | $2.1B | $2.4B | ||
| Q2 25 | $1.9B | $2.5B | ||
| Q1 25 | $2.0B | $2.5B | ||
| Q4 24 | $1.9B | $2.5B | ||
| Q3 24 | $2.1B | $2.5B | ||
| Q2 24 | $1.8B | $2.5B | ||
| Q1 24 | $1.8B | — |
负债/权益比CENXHAE
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $102.8M | $93.6M |
| 自由现金流经营现金流 - 资本支出 | $67.7M | $87.2M |
| 自由现金流率自由现金流/营收 | 10.7% | 25.7% |
| 资本支出强度资本支出/营收 | 5.5% | 1.9% |
| 现金转化率经营现金流/净利润 | 57.11× | 2.09× |
| 过去12个月自由现金流最近4个季度 | $84.8M | $308.1M |
8季度趋势，按日历期对齐
经营现金流CENXHAE
| Q4 25 | $102.8M | $93.6M | ||
| Q3 25 | $2.0M | $111.3M | ||
| Q2 25 | $7.9M | $17.4M | ||
| Q1 25 | $72.3M | $116.6M | ||
| Q4 24 | $-41.4M | $43.8M | ||
| Q3 24 | $20.1M | $48.8M | ||
| Q2 24 | $11.5M | $-27.4M | ||
| Q1 24 | $-14.8M | — |
自由现金流CENXHAE
| Q4 25 | $67.7M | $87.2M | ||
| Q3 25 | $-18.1M | $106.3M | ||
| Q2 25 | $-15.9M | $13.6M | ||
| Q1 25 | $51.1M | $100.9M | ||
| Q4 24 | $-54.6M | $35.2M | ||
| Q3 24 | $-2.4M | $39.4M | ||
| Q2 24 | $-5.4M | $-33.1M | ||
| Q1 24 | $-44.5M | — |
自由现金流率CENXHAE
| Q4 25 | 10.7% | 25.7% | ||
| Q3 25 | -2.9% | 32.5% | ||
| Q2 25 | -2.5% | 4.2% | ||
| Q1 25 | 8.1% | 30.5% | ||
| Q4 24 | -8.7% | 10.1% | ||
| Q3 24 | -0.4% | 11.4% | ||
| Q2 24 | -1.0% | -9.8% | ||
| Q1 24 | -9.1% | — |
资本支出强度CENXHAE
| Q4 25 | 5.5% | 1.9% | ||
| Q3 25 | 3.2% | 1.5% | ||
| Q2 25 | 3.8% | 1.2% | ||
| Q1 25 | 3.3% | 4.7% | ||
| Q4 24 | 2.1% | 2.5% | ||
| Q3 24 | 4.2% | 2.7% | ||
| Q2 24 | 3.0% | 1.7% | ||
| Q1 24 | 6.1% | — |
现金转化率CENXHAE
| Q4 25 | 57.11× | 2.09× | ||
| Q3 25 | 0.13× | 2.88× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | 2.43× | 2.01× | ||
| Q4 24 | -0.92× | 1.17× | ||
| Q3 24 | 0.42× | 1.44× | ||
| Q2 24 | — | -0.71× | ||
| Q1 24 | -0.06× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CENX
| Aluminum | $566.3M | 89% |
| Alumina | $67.4M | 11% |
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
